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Receptor-interacting protein kinase 3 (RIPK3)-mediated necropto-
sis is thought to be the pathophysiologically predominant path-
way that leads to regulated necrosis of parenchymal cells in
ischemia–reperfusion injury (IRI), and loss of either Fas-associated
protein with death domain (FADD) or caspase-8 is known to sen-
sitize tissues to undergo spontaneous necroptosis. Here, we dem-
onstrate that renal tubules do not undergo sensitization to
necroptosis upon genetic ablation of either FADD or caspase-8
and that the RIPK1 inhibitor necrostatin-1 (Nec-1) does not protect
freshly isolated tubules from hypoxic injury. In contrast, iron-
dependent ferroptosis directly causes synchronized necrosis of renal
tubules, as demonstrated by intravital microscopy in models of IRI
and oxalate crystal-induced acute kidney injury. To suppress fer-
roptosis in vivo, we generated a novel third-generation ferrostatin
(termed 16-86), which we demonstrate to be more stable, to me-
tabolism and plasma, and more potent, compared with the first-
in-class compound ferrostatin-1 (Fer-1). Even in conditions with
extraordinarily severe IRI, 16-86 exerts strong protection to an
extent which has not previously allowed survival in any murine
setting. In addition, 16-86 further potentiates the strong protec-
tive effect on IRI mediated by combination therapy with necro-
statins and compounds that inhibit mitochondrial permeability
transition. Renal tubules thus represent a tissue that is not sensi-
tized to necroptosis by loss of FADD or caspase-8. Finally, ferrop-
tosis mediates postischemic and toxic renal necrosis, which may be
therapeutically targeted by ferrostatins and by combination therapy.
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Regulated cell death may result from immunologically silentapoptosis or from immunogenic necrosis (1–3). Necroptosis,
the best-characterized pathway of regulated necrosis, involves
activation of receptor-interacting protein kinase 3 (RIPK3)-
mediated phosphorylation of mixed lineage kinase domain-like
protein (pMLKL) and subsequent plasma-membrane rupture,
which was demonstrated in several disease states, including
ischemia–reperfusion injury (IRI) in all organs analyzed (2–6);
however, none of these previous studies clearly investigated the
mode of cell death in the primary parenchymal cells. Therefore,
it remained possible that the protective effects reported upon
application of the necroptosis inhibitor necrostatin-1 (Nec-1)
and for RIPK3-ko mice involve vascular, nonparenchymal effects.
This possibility has been ruled out in non-IRI settings by condi-
tional tissue targeting of proteins involved in the prevention of
spontaneously occurring necroptosis, such as RIPK1, and com-
ponents that regulate its ubiquitinylation status [linear ubiq-
uitinylation chain assembly complex (LUBAC), cellular inhibitors
of apoptosis proteins (cIAPs)), caspase-8, and Fas-associated
protein with death domain (FADD)] in the gastrointestinal tract
(7, 8), the skin (9, 10), the liver (11), and immune cells (12, 13), all
of which result in spontaneous RIPK3-mediated tissue necroptosis
and inflammation (7–9, 11, 12, 14–17).
Ferroptosis is an iron-dependent necrotic type of cell death
that occurs due to lipid peroxide accumulation, which routinely is
prevented by glutathione peroxidase 4 (GPX4), a glutathione-
(GSH)-dependent enzyme, and therefore depends on the func-
tionality of a glu/cys antiporter in the plasma membrane referred
to as system Xc-minus (18–20). Ferroptosis has been reported to
cause several diseases and may be interfered with in vitro by the
small molecule ferrostatin-1 (Fer-1) (18); however, Fer-1 was
suggested to have low in vivo functionality due to potential
metabolic and plasma instability.
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Cell death by regulated necrosis causes tremendous tissue
damage in a wide variety of diseases, including myocardial
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iron-dependent form of regulated necrosis, referred to as fer-
roptosis, mediates regulated necrosis and synchronized death
of functional units in diverse organs upon ischemia and other
stimuli, thereby triggering a detrimental immune response. We
developed a novel third-generation inhibitor of ferroptosis
that is the first compound in this class that is stable in plasma
and liver microsomes and that demonstrates high efficacy
when supplied alone or in combination therapy.
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In the present studies, we used inducible, conditional kidney
tubule-specific genetic deletion of FADD and caspase-8, in-
travital microscopy, fresh isolation of primary kidney tubules,
and four preclinical models of acute organ failure to further
assess the relative roles of necroptosis and ferroptosis. We find
that ferroptosis is of functional in vivo relevance in acute tubular
necrosis and IRI, and we introduce, to our knowledge, the first
ferroptosis inhibitor that is applicable for inhibition of ferrop-
tosis in vivo. We conclude that specific combinatory therapies
will be most promising for the prevention of clinically relevant
IRI and that the nephron represents, to our knowledge, the first
described tissue that is not sensitized to necroptosis by loss of
FADD or caspase-8.
Results
Conditional Deletion of FADD or Caspase-8 Does Not Induce Cell
Death in Renal Tubular Epithelia. The mode of cell death of tubu-
lar cells in acute kidney injury (AKI) has been a matter of intense
discussion (21, 22). Because RIPK3-deficient mice have been
shown to be partially protected from IRI-induced tubular ne-
crosis (4, 23) and because Nec-1 phenocopies this effect (21, 24,
25), it was hypothesized that necroptosis might be the mode of
cell death that drives parenchymal cells into necrosis. However,
it was not ruled out that tubular cell death might have occurred
secondary to some changes outside the tubular compartment:
e.g., in RIPK3-dependent organ perfusion, which might be altered
also upon Nec-1 treatment if the necroptotic pathway was in-
volved. In fact, a discrepancy between the strong in vivo pro-
tection and the marginal protective effect of RIPK3-deficient
freshly isolated tubules would be consistent with this hypothesis
(4). A powerful approach to definitively study the involvement
of cell-specific necroptosis is to delete components of the nec-
roptosis-suppressing complex, which consists of FADD, caspase-
8, RIPK1, and FLIP (26, 27), and to analyze spontaneously
occurring necroptosis. We therefore crossed tubular cell-specific
inducible conditional mice (Pax8-rtTA Tet-on.Cre) (28) to
FADD or capase-8 floxed mice (Fig. S1 A–E) and confirmed the
deficiency of the protein of interest by Western blotting from
freshly isolated renal tubules (Fig. 1 A and B and D and E),
which were carefully confirmed to be devoid of any other cells
(Fig. S2). Unlike in all other tissues reported so far, inducible
deletion of FADD or caspase-8 in Pax8-rtTA; Tet-on.Cre ×
FADD fl/fl and Pax8-rtTA; Tet-on.Cre × caspase-8 fl/fl mice did
not affect serum markers of renal function (Fig. 1G and Fig.
S1F), histological appearance (Fig. 1 C and F), or organ function
for the entire observation period of 3 wk after addition of doxy-
cyclin into the drinking water (Fig. 1G and Fig. S1F). After the
3-wk period of doxycyclin feeding, mice were morphologically
indistinguishable from nondoxy-fed littermates (Fig. S1E). In
addition, induction of acute kidney injury by application of the
nephrotoxin cisplatin (20 mg/kg body weight) led to similar
survival kinetics as in WT mice (Fig. 1H). In freshly isolated
renal tubules treated with 50 μM Nec-1, no protection was
detected both in the presence or in the absence of glycine (Fig.
1I). This result is in line with our previous observation of low
levels of RIPK3 in tubular cell lines (21) and marginal sensitivity
for necroptosis compared with a glomerular endothelial cell line
and L929 fibrosarcoma cells (21). Taken together, these data
strongly argue against necroptosis as the primary mode of regulated
cell death in renal tubules and suggest that the effects in RIPK3-ko
and Nec-1–treated mice are due to extratubular effects.
RIPK3-Deficient Mice Exhibit Increased Renal Perfusion and Fail To
Gain Normal Body Weight. Using low-resolution intravital micros-
copy, we previously investigated the effects of Nec-1 on the di-
ameter of peritubular capillaries (22). Using a similar approach
with higher resolution (Fig. S3A), we have now analyzed RIPK3-
ko mice and detected statistically significant increases in peri-
tubular diameters (Fig. S3 B and C), which would account for
25.7% increase in blood flow (Fig. S3D) according to the law of
Hagen Poiseuille and could help maintain peritubular perfusion
after ischemia when it is known to be compromised. Taking into
consideration that, in all renal cells investigated, the highest
RIPK3 expression was found in endothelial cells, vascular effects
cannot be ruled out, and endothelial cell-specific conditional
RIPK3 depletion should be investigated in IRI models. In this
respect, it is noteworthy that, in another model of necrotic pa-
renchymal damage that does not rely on ischemia–reperfusion
Fig. 1. Conditional deletion of FADD or caspase-8
does not sensitize renal tubules to necroptosis. (A)
Scheme of the doxycyclin-inducible conditional
tubular knockout. (B) After 3 wk of doxycyclin-
treatment, no detection of the FADD protein in
freshly isolated renal tubules was possible; L929
cells serve as a positive control. (C) Periodic acid–
Schiff (PAS) staining of normal renal morphology in
Pax8-rtA; Tet-on.Cre × FADD fl/fl mice after 3-wk
treatment with doxycyclin via the drinking water.
(D–F) Similarly, caspase-8 was inducibly depleted
from tubules. Note that the anti-mouse mono-
clonal antibody against caspase-8 cross-reacts with
a nonspecific protein just below the band of cas-
pase-8. Mouse embryonic fibroblasts (MEFs) from
caspase-8/RIPK3-dko mice serve as a negative con-
trol, MEFs from cyclophilin D-deficient ppif-ko mice
serve as a positive control, as do the C57BL/6 WT
mice. (G) Serum creatinine levels remain in the
normal range in all mice investigated as indicated. (H)
Doxycyclin-induced conditional FADD-deficient or
caspase-8–deficient mice react to 20 mg/kg body
weight cisplatin-induced acute kidney injury simi-
larly to nonstimulated mice. (I) Necrostatin-1 (Nec-1;
50 μM) does not influence the amount of LDH re-
leased from hypoxic renal tubules, either in the
presence (Left) or absence (Right) of glycine (glc) (n =
8–10 per group).











injury, the cerulein-induced pancreatitis, in our hands, RIPK3-
deficient mice are not protected from the increase in serum
levels of amylase and lipase (Fig. S3E). In addition, we noticed
that RIPK3-ko mice fail to gain normal body weight in com-
parison with WT littermates in both males and females (Fig. S3 F
and G).
Morphological Changes of Synchronized Tubular Cell Death Are
Prevented by Ferrostatins. If apoptosis and necroptosis account
for only minor damage of acute tubular necrosis, we asked what
pathway of regulated necrosis might be causative of synchronized
tubular death that we identified in an improved ex vivo model of
freshly isolated murine renal tubules upon depletion of fatty
acids (Fig. 2A and Movie S1). We confirmed such tubules to be
functional before the onset of the fatty-acid depletion for max-
imal control purposes (Movie S2). Importantly, such synchro-
nized tubular (cell) death very much resembles the appearance
of casts found in urine sediments of patients with acute kidney
injury. The dynamics of the tubular necrosis suggest a direct cell-
to-cell communication to deliver the deadly signal (Movie S3).
Because we previously reported a beneficial effect of the second-
generation ferrostatin 11-92 (29) in a model of acute injury of
freshly isolated renal tubules, we looked for the morphology of
such tubules in the presence of erastin, a well-described inducer
of ferroptosis, a necrotic type cell death that largely depends
on lipid peroxidation (18, 19), over time (Fig. 2B). Whereas the
Fig. 2. Ferroptosis mediates synchronized tubular necrosis and contributes to immune-cell extravasation into ischemic tissue. (A) Snapshots from Movie S1 of
functional freshly isolated proximal renal tubule segments undergoing rapid synchronized necrosis upon fatty-acid depletion. (B) In the presence of fatty
acids, addition of erastin accelerated, whereas 16–86 (a third-generation ferrostatin; see Fig. 3) prevented, tubular necrosis. (C) During the time course of
hydroxyquinoline/Fe-induced tubular necrosis, Fer-1 and the Nox-inhibitor GKT prevented LDH release whereas Nec-1 did not show protection. (D) Reflected
light oblique transillumination imaging of leukocyte passages through postcapillary venules in IRI of the cremaster muscle in the presence of vehicle or Fer-1.
(E) FITC dextran leakage in the same model. (F) Leukocyte rolling is affected by Fer-1 within the first hour after reperfusion. (G) Significantly reduced leu-
kocyte transmigration in the presence of Fer-1.
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faint plasma membrane of untreated tubules did not change in
16-86–treated tubules [a novel third-generation ferrostatin we
generated (Fig. 3)], vehicle-treated and especially erastin-treated
tubules showed membrane protrusions and obvious signs of de-
formation and functional insufficiency (Fig. 2B). When erastin
was applied into the tubule, a similar type of cell death occurred
even without fatty-acid depletion (Movie S4). In another well-
established lactate dehydrogenase (LDH) release-based assay of
ex vivo tubulotoxicity (29), hydroxyquinoline–iron-induced cell
death, we found Fer-1 and the Nox-inhibitor GKT to be pro-
tective whereas Nec-1 did not show any protection (Fig. 2C).
Ferroptosis Mediates IRI-Mediated Immune-Cell Infiltration of the
Cremaster Muscle. The concept of immunogenic necrotic cell death
proposes to trigger an autoamplification loop, which is triggered by
a necroinflammatory microenvironment. To understand how fer-
roptosis attracts immune cells during hypoxia/reperfusion situations,
we performed musculus cremaster IRI assays and read out the
immune-cell infiltration by intravital microscopy (Fig. 2 D–F) and
quantified rolling, adherent, and transmigrated cells in the presence
and absence of ferrostatins (Fig. 2 F and G and Fig. S4 A and B).
Less immune-cell infiltration into the postischemic area suggested
either that Fer-1 directly inhibits leukocyte transmigration or that
the local proinflammatory microenvironment was less chemo-
attractive, presumably by less damage-associated molecular pattern
(DAMP) release due to less ferroptotic cell death.
Ferroptosis Mediates Tubule Necrosis in Oxalate Nephropathy, but
Not in an LPS-Induced Septic Shock Model. Having identified fer-
roptosis to be of relevance in acute postischemic injury, we
sought to investigate another model of acute renal failure, oxa-
late nephropathy, which has recently been established (30).
Intrarenal CaOx crystal deposition was identical in all groups
(Fig. S5 A and B). However, neutrophil infiltration and expres-
sion levels of proinflammatory cytokines (CXCL-2, IL-6), kidney
injury molecule 1 (KIM-1), and the p65 subunit of NF-κB were
statistically significantly reduced upon a once daily i.p. applica-
tion of Fer-1 (Fig. S5E). Importantly, Fer-1 also significantly
reduced the tubular injury score (Fig. S5D) and the functional
serum markers of kidney injury creatinine and urea (Fig. S5C).
Because RIPK3-deficient mice have been demonstrated to be
resistant to sepsis models, we also investigated Fer-1 in the
model of LPS-induced shock (Fig. S5F), but no difference com-
pared with vehicle-treated mice was evident. Therefore, fer-
roptosis seems to be a valuable target for both postischemic
and toxic acute kidney injury. However, given the poor plasma
stability of Fer-1, we sought to develop a more stable com-
pound for the in vivo applications.
Generation of a Third-Generation Ferrostatin with Increased Plasma
and Metabolic Stability for in Vivo Studies. Given the promising
results of the cremaster–IRI and oxalate nephropathy studies
and the previously published efficacy of second-generation fer-
rostatins in models of Huntington´s disease, periventricular
leukomalacia, and tubular necrosis (29), we wondered whether
the reported poor plasma stability of Fer-1 could be further
enhanced by structure-relation analysis. We therefore first
evaluated the in vitro metabolic stability of one of the highly
potent Fer-1 analogs, SRS15-72B (29), in liver microsomes of
mice. SRS15-72B was cleared rapidly with a half-life of t1/2 = 2
min (Table S1). To achieve a more metabolically stable Fer-1
analog, we created an imine-type structure (SRS15-72A) that
showed high stability in microsomes with a half-life of t1/2 = 154
min (Table S2). This metabolically stable analog turned out not
to be sufficiently stable in the plasma due to its ethyl ester moiety
(Table S3), a functional group well-known to be more susceptible
to hydrolysis in plasma (31). Because a previous study showed
that the ethyl ester is important to maintain the potency of
Fer-1, we aimed at improving the plasma stability, while
maintaining high microsomal stability by creating additional
imine analogs with isopropyl (SRS16-80) and tert-butyl (SRS16-
86) esters (Fig. 3A). These analogs allowed us to comparatively
study the plasma stability of the ethyl, isopropyl, and tert-butyl
esters, respectively. Among these three ester analogs (SRS15-
72A, SRS16-80, and SRS16-86), the tert-butyl ester analog
(SRS16-86) showed the highest stability in plasma (Table S4). In
addition, SRS16-86 maintains high stability in the microsomal
compartment [intrinsic clearance (CLint) (mL/min per g liver <
0.5)] (Table S5). For in vivo experiments, we therefore used 16-
86 and used it in comparison with 16–79, an inactive derivate
(Fig. 3B). We confirmed the ferroptosis-inhibiting ability of 16-
86 and 16-79 in vitro by FACS analysis of erastin-treated HT-
1080 cells and in NIH 3T3 cells (Fig. 3C). In both necroptosis
and ferroptosis, we failed to detect cleaved caspase 3 (Fig. 3D).
Ferroptosis Mediates Necrotic Tubular Cell Death in Renal Ischemia–
Reperfusion Injury.We applied active (16-86) and inactive (16-79)
compounds to a model of severe ischemia–reperfusion injury
(IRI), which we described before (4). Upon 40 min of ischemia
before reperfusion, we know that all WT mice die between 48 h
and 72 h, which can be anticipated from the 48-h serum creati-
nine values above 2.0 mg/dL. As demonstrated in Fig. 4 A–D,
creatinine levels of all vehicle-treated C57BL/6 mice exceeded
2.0 mg/dL and showed strong morphologic damage and high
serum urea levels whereas Fer-1–treated and, to a greater extent,
Fig. 3. Generation and in vitro testing of a ferrostatin derivative for in vivo
applications. (A) Synthetic route of the most microsomal and plasma stable
ferrostatin analog (SRS16-86). (B) Model structure of the two novel ferrostatin
derivates SRS16-79 (inactive compound) and SRS16-86 (active compound). (C)
FACS analysis for the necrotic marker 7AAD and phosphatidylserine accessibility
(annexin V) in HT1080 and NIH 3T3 cells treated with either vehicle or 50 μM
erastin in the presence or absence of 1 μM Fer-1, 16-86, or 16-79. (D) Absence of
cleaved caspase-3 in necroptosis and ferroptosis. Western blot of cleaved cas-
pase-3 in lysates from 100 ng/mL TNFα plus 1 μM Smac mimetics plus 25 μM
zVAD-treated HT-29 cells, 50 μM erastin-treated NIH 3T3 cells, and 50 μM era-
stin-treated HT1080 cells for 24 h. Monoclonal anti-Fas–treated Jurkat cells
(100 ng/mL) served as positive control. TSZ, TNFa/SMAC-mimetic/zVAD.











16-86–treated mice were protected from functional acute renal
failure (Fig. 4 C and D) and structural organ damage (Fig. 4 A
and B) after IRI. Mice treated with 16–79 in a similar manner
did not show any differences compared with the vehicle-treated
controls. We did not observe any side effects from treatment
with the same dose of 16-86 4 wk after application. The effect of
16-86 exceeded that of any single compound we previously ex-
perienced to be protective from renal IRI.
Ferrostatins Further Increase the Protective Effect of [Necrostatin-1/
Sanglifehrin A] Combination Therapy in Renal IRI. Given that Nec-1
protects from renal IRI to a lesser extent than 16-86, and given
that interference with mitochondrial permeability transition
(MPT)-induced regulated necrosis (MPT-RN) by the compound
sanglifehrin A (SfA) also mildly protects from IRI, with marked
additive protective effects in combination therapy with Nec-1 (4,
5), we sought to further extend the combination therapy by
investigating the influence of 16-86 and 16-79 in [Nec-1 +
SfA]-treated mice. Because the effect of the [Nec-1 + SfA]
treatment could be investigated only in a severe ischemia
model and we aimed to investigate additive protective effects
by 16-86, we further increased the ischemic duration to
a model of ultrasevere IRI (see Materials and Methods for
details). In such settings, even the combination therapy with
[Nec-1 + SfA] did not fully rescue creatinine values and organ
damage (Fig. 4 E–H). Addition of 16-86, but not 16-79, reduced
plasma levels of serum urea and serum creatinine, suggesting
that a triple combination therapy with [Nec-1 + SfA] plus 16-86
is superior in the prevention of renal IRI compared with the
double-combination therapy with [Nec-1 + SfA]. In addition,
this result indicates either that at least three independent
pathways of regulated necrosis may be involved in IR-mediated
organ damage or that inhibition of overlapping elements with
SfA and Nec-1 are incomplete.
Discussion
Parenchymal cell necrosis, but not apoptosis, which seems to be
minimally involved in the pathogenesis of acute kidney injury
(32), triggers the release of DAMPs, some of which can trigger
regulated necrosis and therefore initiate a necroinflammatory
feedback loop. In clinical routine, immunosuppression is a stan-
dard procedure, but an anti-cell death therapy does not exist
apart from cyclosporine (5). Therefore, defining the precise
mechanisms that trigger regulated necrosis is essential for the
development of new drugs. Our data indicate that alternative
interpretations apart from “pure” necroptosis exist and suggest
that ferroptosis is of importance in renal tubules, which, other
than the skin, the gastrointestinal tract, or immune cells, do not
depend on a necroptosis-inhibiting complex, at least not of
FADD and caspase-8. To date, it cannot be ruled out that pre-
viously described protection against ischemia–reperfusion injury
in diverse organs is mediated by increased perfusion rather than
direct protection from parenchymal necroptosis. Our results re-
garding the cerulein-induced pancreatitis are in line with this
Fig. 4. Ferroptosis significantly contributes to renal ischemia–reperfusion injury. (A and B) Representative PAS stainings and quantification of renal damage
from mice treated with severe ischemic durations before reperfusion. Mice were killed 48 h after reperfusion. (C and D) Functional markers of acute kidney
injury after severe IRI (as in A and B). (E and F) Histologic PAS staining and quantification of sham operation or ultrasevere IRI (50 min of ischemia before
reperfusion) in WT mice treated with [Nec-1 + SfA] combination therapy together with either 16-79 or 16-86. (G and H) C57BL/6 were treated as in E, and
functional markers of acute kidney injury were measured 48 h after the onset of reperfusion. n.s., not significant; *P = 0.05–0.02, **P = 0.02–0.001, ***P ≤
0.001; n = 10 per group in all experiments).
16840 | www.pnas.org/cgi/doi/10.1073/pnas.1415518111 Linkermann et al.
hypothesis and are in contrast to previously published data
(33, 34). Several unanswered questions remain: Why are RIPK3-
deficient mice protected in several models of IRI if the paren-
chymal cells do not undergo necroptosis? Why do necrostatins
protect such tissues from organ failure if necroptosis is not the
predominant mechanism of parenchymal cell death? Endo-
thelial cell-specific deletion of RIPK3 will help to answer these
open questions.
Materials and Methods
See SI Materials and Methods for detailed descriptions.
Mice. All WT mice reported in this study were on C57BL/6 background. Eight-
to 12-wk-old male C57BL/6 mice (average weight ∼23 g) were used for all WT
experiments, unless otherwise specified. Caspase-8 fl/fl mice were kindly
provided by Razquella Hakem (Department of Medical Biophysics, University
of Toronto, Toronto and Ontario Cancer Institute, University Health Net-
work, Toronto). FADD fl/fl mice were generated by and provided by M.P.
Doxycyclin-inducible renal tubule-specific Pax8-rtTA; Tet-on.Cre mice have
been published (28) and were kindly provided by Tobias B. Huber (Renal
Division, University Medical Center Freiburg, Freiburg, Germany). RIPK3-
deficient mice were kindly provided by Vishva M. Dixit (Genentech, San
Francisco, CA). All in vivo experiments were performed according to the
Protection of Animals Act, after approval of the German local authorities or
the Institutional Animal Care and Use Committee (IACUC) of the University
of Michigan, and the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (35), after approval from the University of
Michigan IACUC or by the local authorities responsible for the approval at
Ghent University. In all experiments, mice were carefully matched for age, sex,
weight, and genetic background.
Histology, Immunohistochemistry, and Evaluation of Structural Organ Damage.
Organs were dissected as indicated in each experiment and infused with
4% (vol/vol) neutral-buffered formaldehyde, fixated for 48 h, dehy-
drated in a graded ethanol series and xylene, and finally embedded in
paraffin. Stained sections were analyzed using an Axio Imager micro-
scope (Zeiss). Kidney damage was quantified by two experienced pathol-
ogists in a double-blind manner on a scale ranging from 0 (unaffected
tissue) to 10 (severe organ damage). The following parameters were
chosen as indicative of morphological damage to the kidney after is-
chemia–reperfusion injury (IRI): brush border loss, red blood cell ex-
travasation, tubule dilatation, tubule degeneration, tubule necrosis,
and tubular cast formation. These parameters were evaluated on a scale
of 0–10, which ranged from not present (0), mild (1–4), moderate (5 or
6), severe (7 or 8), to very severe (9 or 10). Each parameter was de-
termined on at least four different animals.
Statistics. For all experiments, differences of datasets were considered
statistically significant when P values were lower than 0.05, if not other-
wise specified. Statistical comparisons were performed using the two-
tailed Student t test. Asterisks are used in the figures to specify statistical
significance (*P < 0.05; **P < 0.02; ***P < 0.001). P values in survival
experiments (Kaplan–Meier plots) were calculated using GraphPad Prism,
ver. 5.04 software. Statistics are indicated as SD unless otherwise specified.
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